OPKO Health (NASDAQ:OPK) Announces Earnings Results

OPKO Health (NASDAQ:OPK) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.03, Zacks reports. OPKO Health had a negative net margin of 28.10% and a negative return on equity of 13.67%. The business’s revenue was down 19.1% on a year-over-year basis. During the same quarter last year, the business posted $0.01 earnings per share.

Here are the key takeaways from OPKO Health’s conference call:

• OPKO completed a second major asset sale of BioReference’s oncology assets and repositioned BioReference as a streamlined, regionally focused clinical lab with a national 4Kscore franchise, which management says positions the diagnostics business for sustained profitable growth in 2026.
• The company struck a collaboration with Regeneron (potentially >$1 billion in milestones plus royalties) and has an EBV vaccine partnership with Merck, providing non-dilutive funding and external development/commercial support for ModeX programs.
• ModeX clinical progress: MDX-2001 has dosed >25 patients with dose escalation showing tolerability and early efficacy signals, MDX-2004 (immune rejuvenator) and MDX-2003 (CD19/CD20 tetraspecific) are in/entering Phase 1, and multiple readouts/phase advances are expected through 2026.
• OPKO entered 2026 with a strong liquidity position (reported $369 million in cash/restricted cash) and an active buyback program (34.6M shares repurchased in 2025; ~$113M remaining authorization), which management is using alongside R&D investments.
• Financial headwinds remain as Q4 revenue declined to $148.5M (from $183.6M) after the divestiture, Q4 net loss was $31.3M, and full-year 2026 guidance implies heavy spending with total costs of $725M–$750M driven by increased R&D investment.

OPKO Health Stock Up 1.7%

Shares of OPK traded up $0.02 during trading hours on Thursday, reaching $1.20. The company’s stock had a trading volume of 2,137,750 shares, compared to its average volume of 2,457,783. The company has a 50 day moving average of $1.27 and a two-hundred day moving average of $1.36. The company has a quick ratio of 3.32, a current ratio of 3.70 and a debt-to-equity ratio of 0.25. The firm has a market cap of $921.24 million, a price-to-earnings ratio of -4.80 and a beta of 1.47. OPKO Health has a 1-year low of $1.11 and a 1-year high of $2.04.

Analyst Upgrades and Downgrades

OPK has been the topic of several recent research reports. Jefferies Financial Group restated a “hold” rating and issued a $1.60 price target (down from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. Barrington Research reaffirmed an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research report on Thursday, October 30th. Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a research report on Sunday, December 21st. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. assumed coverage on shares of OPKO Health in a report on Thursday, November 20th. They issued a “neutral” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, OPKO Health has a consensus rating of “Hold” and an average price target of $2.28.

Institutional Investors Weigh In On OPKO Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. StoneX Group Inc. purchased a new position in shares of OPKO Health during the 4th quarter valued at $27,000. Zacks Investment Management acquired a new stake in OPKO Health during the fourth quarter valued at $27,000. Cibc World Markets Corp purchased a new position in OPKO Health in the fourth quarter valued at about $34,000. EP Wealth Advisors LLC purchased a new position in OPKO Health in the fourth quarter valued at about $37,000. Finally, Norges Bank purchased a new stake in shares of OPKO Health during the 2nd quarter worth about $52,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.